Under certain conditions, C57BL/6 mice persistently infected with mouse hepatitis virus strain JHM (MHV-JHM) develop clinical disease and histological evidence of demyelination several weeks after inoculation with virus. In a previous report, we showed that mutations in the RNA encoding an immunodominant CD8 T-cell epitope within the surface glycoprotein (epitope S-510-518) were present in all persistently infected animals and that these mutations abrogated recognition by virus-specific cytotoxic T cells (CTLs) in direct ex vivo cytotoxicity assays. To obtain further evidence that these mutations were necessary for the development of clinical disease, the temporal course of their appearance was determined. Mutations in the epitope were identified by 10 to 12 days after inoculation, and in some mice, virus containing mutated epitope was the dominant species detected by 15 days. In addition, most mice that remain asymptomatic at 80 days after inoculation, a time after which clinical disease almost never develops, were infected with only wild-type virus. Finally, analysis of virus isolated from mice with severe combined immunodeficiency (SCID) revealed the presence only of wild-type epitope S-510-518. These results, by showing that mutations are not selected in SCID mice and occur at early times after inoculation in C57BL/6 mice, support the view that they result from immune pressure and contribute to virus persistence and demyelination in mice infected persistently with MHV-JHM.
Mouse hepatitis virus strain JHM (MHV-JHM), a member of the coronavirus family, causes acute and chronic neurological infections in susceptible rodents (13, 18) . Most strains of mice develop an acute encephalitis after intracerebral or intranasal inoculation with virulent versions of this virus. This acute, invariably fatal encephalitis can be prevented if mice are inoculated with attenuated virus or are protected by administration of antiviral antibody or T cells (13, 18) . Under these conditions, mice do not develop acute disease but in many cases, they become chronically infected. This chronic infection is usually asymptomatic or mildly symptomatic and is characterized histologically by demyelination without axon death. Lymphocytic infiltrates and large numbers of activated macrophages/microglia are present in the lesions. Tumor necrosis factor alpha (TNF-␣), interleukin-6 (IL-6), IL-1␤, and the inducible form of nitric oxide synthase can be detected in astrocytes located near areas of demyelination (25, 36) . Similar findings are present in the central nervous system (CNS) of patients with multiple sclerosis (MS) (37) , and these chronically infected mice serve as an animal model for this human disease.
In one model of MHV-JHM-induced chronic neurological disease, suckling C57BL/6 (B6) mice are infected with MHV-JHM intranasally (27) . They are protected from acute encephalitis by nursing with dams previously immunized with infectious MHV-JHM. These mice remain asymptomatic for an extended period of time, but 40 to 90% develop hindlimb paralysis and histological evidence of demyelination 3 to 8 weeks after inoculation. In this regard, mice chronically infected with MHV-JHM in the presence of protective maternal antibody are different from other mice chronically infected with MHV since in the majority of other models, mice are most symptomatic a few days after inoculation and then recover. Furthermore, in mice protected with maternal antibody, infectious virus can be isolated from symptomatic but not asymptomatic mice, but viral antigen and RNA can be detected in nearly all mice, whether symptomatic or not. This is also in contrast to other MHV models in which virus can be cultured only at early times postinoculation (p.i.) (13, 16, 18) .
Cytotoxic CD8 T lymphocytes (CTL) are important in virus clearance, and mutations in CTL epitopes should enhance virus escape from immune surveillance (10, 23, 43) . The biological significance of CTL escape mutants has remained an area of controversy, however, since the CTL response in most infections is directed at multiple epitopes, and mutations in a single epitope would not be expected to result in a significant delay in virus clearance (10, 31) . CTL escape mutants have been shown to result in delayed virus clearance in mice infected with lymphocytic choriomeningitis virus (LCMV) in which the number of CTL epitopes is limited and may also be important in a minority of patients chronically infected with hepatitis B virus or human immunodeficiency virus type 1 (HIV-1) (3, 4, 10, 15, 19, 21, 29, 30, 41) .
Recently, we and others identified two dominant CTL epitopes recognized in B6 mice infected with MHV-JHM (2, 7). Both epitopes are present within the surface glycoprotein (S) and one, encompassing residues 510 to 518 (S-510-518), is significantly more potent at sensitizing cells for lysis in primary CTL assays. S-510-518 is located in a hypervariable region of the S glycoprotein (1, 24, 32) , and in a previous publication, we showed that mutations in the RNA encoding this epitope can be detected in nearly all samples isolated from symptomatic mice chronically infected with MHV-JHM (28). Mutations could not be detected in the sequences encoding either the second CTL epitope or a previously identified CD4 epitope located within the transmembrane (M) protein or in the 200 nucleotides surrounding each of the three epitopes. We also showed that several of these mutations resulted in a loss of recognition by lymphocytes harvested from the CNS of mice with acute encephalitis when analyzed in direct ex vivo cytotoxicity assays.
These mutations result in loss of recognition by CD8 T cells, but whether they contribute to persistence or develop after persistence has occurred for other reasons was not evident from these data. If these changes contribute to persistence, they should be detected by the time virus clearance normally occurs. From previous studies, it is known that MHV-JHM is cleared by approximately 13 to 21 days after intracerebral inoculation (12, 13, 16, 18) , and it can be anticipated that clearance after intranasal inoculation occurs in a similar or slightly longer time period. Furthermore, if mutations in epitope S-510-518 occur as a consequence of immune selection, they should not be present in virus isolated from persistently infected mice lacking a CD8 T-cell response to this epitope. Mice with severe combined immunodeficiency (SCID) become persistently infected with MHV-JHM and should be useful for proving this point.
MATERIALS AND METHODS
Virus. MHV-JHM, used in all experiments, was grown and titered as previously described (27) . To obtain virus from infected mice, brains and spinal cords were harvested and sonicated in Dulbecco's minimal essential medium. After removal of large debris by centrifugation, samples were passaged at a 1:10 dilution through DBT cells (a murine astrocytoma cell line) and analyzed as described below. In some cases, a fraction of each tissue was analyzed for infectious virus and the remainder used for isolation of RNA.
Animals. Pathogen-free B6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine) and Harlan Sprague Dawley (Indianapolis, Ind.). To obtain persistently infected mice, suckling mice were inoculated intranasally with 2 ϫ 10 4 to 6 ϫ 10 4 PFU of MHV-JHM and nursed by dams previously immunized with live MHV-JHM as described previously (27) . Six-week-old C.B-17-scid (SCID) mice were obtained from D. Lubaroff, University of Iowa. To obtain persistently infected SCID mice, a mixture of two anti-S neutralizing antibodies (monoclonal antibody [MAb] 5A13.5 [neutralizing titer, 1:45,000] and MAb 5B19.2 [neutralizing antibody titer, 1:2,700], both provided by Michael Buchmeier, The Scripps Research Institute) was administered by intraperitoneal inoculation just prior to intranasal inoculation with virus. Three mixtures of antibodies (100 l of each of the two antibodies, 50 l of each antibody, or 25 l of MAb 5A13.5 and 75 l of MAb 5A19.2) were used for this purpose, with similar results. As controls for these experiments, dams were passively immunized with 50 to 75 l of a 1:1 mixture of the two antibodies at 7 days postpartum. Virus was then administered intranasally to their offspring at 10 days as described above.
Isolation of RNA from infected CNS tissue and tissue culture cells. RNA was isolated from infected brains and spinal cords and from infected tissue culture cells by using Tri Reagent (Molecular Research Center, Cincinnati, Ohio) as specified by the manufacturer.
Sequence analysis. In all cases, cDNA was synthesized from 1 to 2 g of infected tissue or tissue culture cell RNA. For cDNA synthesis, the RNA was incubated at 40°C for 60 min in a 30-l reaction as previously described (28) . The synthesized cDNA was amplified by PCR, using standard techniques (28) . In some cases, a second amplification step was included if insufficient PCR product was obtained. Primers encompassing nucleotides 1333 to 1352 and 1850 to 1869 were used for this purpose. PCR products were manually sequenced by the Sanger method of dideoxy-mediated chain termination, using the fmol DNA sequencing system as instructed by the manufacturer (Promega, Madison, Wis.). Primers encompassing nucleotides 1333 to 1352 and 1622 to 1641 were used for sequencing (28) . S-specific PCR products were also cloned into the HindIII and PstI sites of pIBI31 (IBI, New Haven, Conn.), using the same primers encompassing nucleotides 1325 to 1343 and 2098 to 2118 (28) . Manual sequencing of cloned cDNA was performed by the dideoxy-chain termination method, using either the fmol sequencing system (Promega) or Sequenase (version 2.0) as recommended by the manufacturer (United States Biochemical, Cleveland, Ohio). The same primers as described above for direct PCR sequencing or a T7 promoter primer (Genosys Biotechnologies, The Woodlands, Tex.) were used for sequencing the S-specific clones.
RESULTS
Mutations in epitope S-510-518 appear by 10 to 12 days p.i. In general, B6 mice develop hindlimb paralysis from 3 to 8 weeks after inoculation with MHV-JHM (27) . Infectious virus can be isolated from these mice, and in every case, virus is mutated in the sequences encoding epitope S-510-518. To determine when mutations in the epitope could first be detected, suckling mice were inoculated with MHV-JHM and protected from acute encephalitis by nursing by dams previously immunized to MHV-JHM. RNA was harvested from asymptomatic mice at 7 to 21 days p.i., since we had showed previously that changes in epitope S-510-518 could be detected at 23 days p.i. (28) . cDNA was prepared from these samples and used to generate PCR products. These were directly sequenced. To detect any sequence heterogeneity, cDNA clones were prepared from some samples and sequenced. To obtain RNA from infectious virus, MHV harvested from infected tissue was amplified by a single passage through DBT tissue culture cells.
As shown in Table 1 , only sequences encoding wild-type epitope S-510-518 could be detected in the RNA of asymptomatic mice at 7 days p.i. This result was not unexpected since only wild-type epitope was present at 6 to 7 days p.i. in the CNS of mice dying from acute encephalitis (28) . Bulk populations of S-specific cDNA and individual clones prepared from these cDNA samples were analyzed in these experiments, and approximately 200 nucleotides containing epitope S-510-518 were sequenced. Rare mutations at random sites outside of epitope S-510-518 were detected in the analysis of cDNA clones. These changes most likely reflect the high error rate of the coronavirus polymerase, although errors introduced by Taq during the amplification process may also have contributed to their appearance.
By days 10 to 12 p.i., however, mutations in the RNA encoding epitope S-510-518 could be detected in some samples. The three-nucleotide deletion (nucleotides 1532 to 1534) observed in the RNA of mouse 176L2-1 harvested at day 10 p.i. was present in only one of 20 clones analyzed, but this change has been identified in virus isolated from mice with hindlimb paralysis (28; see also below) and is unlikely to be an error introduced by Taq polymerase. In the case of mouse 173L3-1, harvested at day 12 p.i., a change in nucleotide 1547, resulting in a proline-to-histidine change at position 7 of the epitope, was present in 4 of 26 clones in RNA isolated from the spinal cord (Table 1) . In this particular sample, two other changes in the epitope were also detected. By day 15 p.i., significant mutations in epitope S-510-518 could be detected either in bulk populations of RNA or in infectious virus harvested from the spinal cords of three of six mice that were analyzed (Table 2) . Virus can occasionally be isolated from asymptomatic mice, and in the analyses shown in Table 2 , only a few samples were assayed for infectious virus. However, in one case (mouse 175L2-2), infectious virus containing a mutation in the RNA encoding epitope S-510-518 was detected at day 15 p.i. This variant virus was not detected by direct sequence analysis of the PCR product synthesized from the spinal cord of this mouse, suggesting that the mutated virus represented a minority of the total viral RNA at this time.
In summary, these results suggest that mutations first appear by 10 to 12 days p.i. and that selection pressure is sufficient so that RNA molecules containing these changes constitute the majority of S-specific viral RNA molecules present in the spinal cords of some mice by 15 days p.i. These mutations become dominant in the same time frame as virus clearance occurs in other models of MHV-induced encephalitis (12, 13, 16, 18) . Of note, these changes were detected in approximately 50% of the mice that were analyzed at 15 days p.i. In this experiment, about 50% of the mice that were not sacrificed for RNA at this time developed hindlimb paralysis later, suggesting that the presence of mutations in epitope S-510-518 was necessary for virus amplification and clinical disease to occur.
Few mutations in epitope S-510-518 are detected in asymptomatic mice harvested at 80 to 90 days p.i. Previously, we found that significant changes in epitope S-510-518 could be detected in one of four mice analyzed at 60 days p.i. (28) . Since mice occasionally develop hindlimb paralysis between 60 and 80 days p.i. (14), brains and spinal cords from an additional 10 asymptomatic mice were harvested at 80 to 90 days p.i. (Table  3) . Infectious virus could not be isolated from any of these mice. No changes were detected in the sequences encoding epitope S-510-518 in seven mice when cDNA product was directly sequenced using PCR, although one of five cDNA clones from one animal (173L2-1) contained a nonsynonymous mutation in epitope S-510-518. This mutation was shown previously to abrogate recognition by CNS-derived lymphocytes in direct ex vivo cytotoxicity assays (28) . In the other three mice, analysis of PCR products by agarose gel electrophoresis suggested the presence of variants containing large deletions in the S gene and in mouse 176L1-3, only deleted product was detected (data not shown). Sequence analysis of the full-length PCR products revealed only wild-type sequence. In each case, sequence analysis of the more rapidly migrating PCR product confirmed the presence of a deletion, and the deletion always included epitope S-510-518. Mice containing these deletions are asymptomatic and by day 90 p.i. are very unlikely to develop clinical disease. Since virus with large deletions can be isolated from mice with hindlimb paralysis (see below), these results suggest that development of mutations in epitope S-510-518 is necessary but not sufficient for virus amplification and the development of clinical disease. They also show that in the majority of mice that remain asymptomatic, the epitope is neither deleted or mutated.
Comparison of epitope S-510-518-specific RNA harvested from spinal cords and infectious virus from the same mouse. Previously, we showed that RNA isolated from persistently infected spinal cords and from infectious virus passaged one to three times in tissue culture cells both contain mutations in epitope S-510-518 (28). These results indicated that passage through tissue culture cells did not select for variant as opposed to wild-type epitope sequence but did not show whether growth in tissue culture cells selected for one variant over another. Previous studies showed that passage through tissue culture cells may select for a subset of virus present in an infected host (20) . To determine if this occurred in MHV-JHM-infected mice with hindlimb paralysis, RNA was prepared from the spinal cord and from infectious virus isolated from the same animal and compared by sequence analysis. As described above, infectious virus was amplified by one passage through DBT cells prior to analysis. The same mutations were detected in infectious virus passaged through tissue culture cells and in spinal cord RNA harvested and analyzed directly (Table 4) . This was most striking in mouse 175L1-1, in which analysis of total PCR product and cDNA clones from spinal cord RNA revealed the presence of two different variant viruses, present in approximately the same proportion. A similar (12) . To determine the role of the immune response in selection of mutations in epitope S-510-518, C.B-17-scid mice (H-2 d haplotype) were infected intranasally with MHV-JHM. These mice, in addition to displaying the SCID phenotype, do not encode the H-2D b protein. Therefore, even if a minor population of mature CD8 T cells develop in these mice (22), they will not recognize epitope S-510-518. To protect mice from acute encephalitis, a mixture of neutralizing antibody was administered intraperitoneally to each animal just prior to virus inoculation, as described in Materials and Methods.
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None of seven SCID mice thus treated developed acute encephalitis (Table 5) . Two mice developed clinical signs of subacute encephalitis, including hunching, ruffled fur, wasting, and hindlimb weakness, at 32 and 39 days p.i. The remaining five asymptomatic mice were harvested at 32 to 63 days p.i. Virus could be detected in all seven mice, and after one passage through DBT cells, RNA was prepared and analyzed for changes in epitope S-510-518. RNA was also prepared from infected brains and spinals cords, and selected analyses of total cDNA and of cDNA clones were performed. As shown in Table 5 , no changes in epitope S-510-518 were detected in any of the samples that were analyzed.
Since these mice were protected from acute encephalitis by direct administration of neutralizing antibody rather than by nursing by immunizing dams, a control group of B6 mice dams were passively immunized 7 days postpartum by intraperitoneal inoculation of 50 l of a 1:1 mixture of the same two neutralizing antibodies. This concentration was chosen since it protected most mice from acute encephalitis but did not prevent the later development of hindlimb paralysis. Three days later, their pups were inoculated intranasally with virus. Fifteen to 20% of the mice thus infected developed hindlimb paralysis several weeks later. As in the pups nursed by dams immunized with live MHV-JHM, virus could be isolated from symptomatic mice. RNA was prepared from infected brains and spinal cords and from infectious virus harvested from these mice with hindlimb paralysis and analyzed for changes in epitope S-510-518 (Table 5 ). The epitope was either mutated or deleted in all cases, with one half of the samples containing large deletions in the S protein. In a previous report, Gallagher et al. showed that treatment in vitro with MAb 5A13.5 selected for antibody-resistant variants that often were deleted in the hypervariable region of the S protein (11) . It is noteworthy that these deletions were seen only in B6 mice and not in SCID mice, raising the possibility that the loss of epitope S-510-518 provided a selective advantage to virus in mice with a normal CTL response to the epitope. In a similar vein, mice lacking a CD8 T-cell response to the S protein would not offer a selective advantage to deleted virus, and wild-type virus might outgrow virus that was deleted (and possibly attenuated).
Mutations in epitope S-510-518 were not selected by exposure to maternally derived antibody or other factors. In all of these experiments, B6 mice were nursed by dams immunized to MHV-JHM. BALB/c mice mount an immunodominant CD8 T-cell response to the nucleocapsid (N) protein. This protein does not contain a hypervariable region, and CTL escape mutants should not be as easily selected as in infected B6 mice. Consistent with this observation, suckling BALB/c mice nursed by actively immunized BALB/c mice do not develop hindlimb paralysis (6). The results described above with SCID mice show that mutations in S-510-518 were not selected as a result of antibody escape, but they did not provide information about other factors, such as maternally-derived T cells, a SCID mice (SCID-1 and SCID-3 to SCID-8) or mice that developed hindlimb paralysis after nursing by dams passively immunized to MHV-JHM (P-1 to P-6). Samples were harvested from spinal cord (SC) or brain (Br).
b Expressed as log 10 PFU per gram of tissue. ND, not determined. c Dpi, day p.i. at which CNS tissue was harvested from mice. d Sequence of either bulk PCR product (bulk) or cDNA clones prepared from the PCR products (clones) from infected tissue or bulk PCR product prepared from infected DBT cells after one passage (virus).
e Number of clones showing indicated sequence over total analyzed. f Nucleotide change and location within sequence encoding epitope S-510-518 (nucleotides 1526 to 1554 of the S gene). g Changes from the wild-type sequence, CSLWNGPHL, are underlined.
that nursing by B6 dams might contribute to the selection process. To show that selection for mutations in epitope S-510-518 was not a consequence of nursing by immunized B6 mice, suckling BALB/c and B6 mice were nursed by immunized B6 and BALB/c dams respectively and infected with MHV-JHM.
As shown in Table 6 , suckling B6, but not BALB/c mice, whether nursed by immunized B6 or BALB/c dams, developed hindlimb paralysis. Changes in epitope S-510-518 were detected in all B6 mice with hindlimb paralysis, whether nursed by B6 or BALB/c mice (data not shown). In another control, suckling BALB/c mice were nursed by BALB/c mice passively immunized with neutralizing antibody as described above and infected with MHV-JHM. Unlike suckling B6 mice nursed by passively immunized B6 mice, no BALB/c mice developed hindlimb paralysis. These experiments support the conclusion that mutations in epitope S-510-518 are selected as a consequence of escape from anti-MHV CD8 T cells arising de novo in the infected pups and not from maternally derived antibody or T cells.
DISCUSSION
The results presented herein in combination with our previous report suggest that cytotoxic T-cell-resistant variants play a key role in the development of clinical disease in B6 mice chronically infected with MHV-JHM. Virus with mutations in the RNA encoding epitope S-510-518 can be detected in all samples of virus and nearly all samples of RNA harvested from the brains and spinal cords of mice with hindlimb paralysis (28) ( Tables 4 and 5) . A CTL response to epitope S-510-518 is required for mutations to occur however, since they do not occur in persistently infected SCID mice (Table 5 ). Of note, mutations have not been detected in epitope S-598-605 (28) . This epitope is also located in the hypervariable region of the S protein, but since peptide corresponding to this epitope is 1/250 as potent as peptide S-510-518 in sensitizing target cells for CTL lysis (7), escape from this epitope might not facilitate increased virus replication, and therefore such mutations would not provide a selective advantage to the virus.
In mice that remain asymptomatic more than 80 days after inoculation and are therefore nearly certain not to develop clinical disease, most viral RNA is not mutated or contains large deletions in the surface glycoprotein (Table 3 ). This region is known to be hypervariable (1, 24, 32) , and in some cases, virus with these deletions has been shown to be attenuated compared to the parental virus (8, 11, 17, 38) . However, since virus with large deletions can be isolated from mice with clinical disease and demyelination (Table 5 ) and virus with missense mutations in the epitope can be detected at 60 days p.i. in asymptomatic mice (28) , loss of recognition by CTLs may be necessary but not sufficient for virus amplification and clinical disease to occur.
While the development of hindlimb paralysis is associated with mutations in epitope S-510-518, the presence of viral RNA encoding the wild-type epitope in the CNS at 80 to 90 days p.i. suggests that MHV-JHM persists in asymptomatic mice even though it remains susceptible to CTLs recognizing epitope S-510-518. A similar conclusion has been reached by Adami et ), even though epitope S-510-518 is not recognized in this strain (6) . The dominant CTL response in B10.A(18R) mice is to an epitope in the nucleocapsid (N) protein. This epitope is also recognized in BALB/c mice (34, 35) , and the fact that hindlimb paralysis never develops in our model in this strain (7) ( Table 6 ), suggests that other genetic factors related to the B6 background are also important in the development of hindlimb paralysis. Similarly, the development of virus persistence and demyelination in mice infected with Theiler's virus is controlled by several host genetic loci, only one of which is linked to the H-2D region of the major histocompatibility complex (5) .
Additional evidence supporting the importance of CTL escape mutants in the pathogenesis of MHV-induced demyelination comes from the detection of mutations in epitope S-510-518 as early as 10 to 12 days p.i. Information about the time course of appearance of CTL escape mutants is available from two studies using mice infected with high doses of LCMV administered intravenously (30, 39) . In one study, mice transgenic for a T-cell receptor (TCR) for LCMV were infected with LCMV. In the second study, mice were immunized with a recombinant vaccinia virus expressing an LCMV CD8 T-cell epitope. Virus was harvested after two passages in these immunized mice. In both reports, CTL escape mutants were dominant by 7 to 8 days p.i., and their appearance correlated with a delay in the kinetics of virus clearance. Notably, in the second report, CTL escape mutants constituted only a small fraction of virus after only one passage through the immunized mice.
In the case of MHV-JHM-infected mice, CTL escape mutants were first detected by 10 to 12 days p.i. and comprised the majority of virus in some animals by day 15 p.i. (Tables 1 and  2 ). This time course of appearance of mutants was similar to that observed in the second report, since two passages of LCMV in immunized mice were required for CTL escape mutants to constitute a majority. The delay of 6 to 8 days compared to the first study is probably due to two factors. First, in the case of the LCMV-infected TCR transgenic mice, the T-cell response to LCMV was monoclonal and these T cells were present at the time of virus inoculation. In mice infected with MHV-JHM, virus-specific CD8 T cells must be selected and propagated. Although it is not known precisely when anti-MHV T cells first appear after intranasal inoculation, antiviral CTL activity can be detected in the spleen as early as 5 days after intranasal inoculation with influenza virus (33) . In mice with MHV-JHM acute encephalitis, infiltrating T cells can be detected by 5 days after intranasal inoculation, and anti-MHV CTL activity is detectable by 6 to 7 days p.i. in direct ex vivo cytotoxicity assays (6, 40) . From these results, one can infer that approximately 5 days are required for MHV-specific CTLs to develop after intranasal inoculation. Second, sufficient virus replication must occur to select and amplify CTL escape mutants. In the LCMV studies, high doses of virus were administered intravenously, whereas we administered lower doses of virus intranasally. After intranasal inoculation, viral RNA can be detected in the olfactory bulb by in situ hybridization at no earlier than 72 h p.i. (reference 26 and unpublished observa- a Dams were immunized with live MHV-JHM as described previously (27) .
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on November 7, 2017 by guest http://jvi.asm.org/ tions). Given these differences in experimental methodology, we conclude that CTL escape mutants arise with similar kinetics in MHV-infected B6 mice and LCMV-infected mice and at sufficiently early times p.i. to have an important role in the process of virus persistence. Since our initial report (28) , additional mutations in epitope S-510-518 have been detected. A summary of the mutations that have been detected thus far and their frequency is shown in Fig. 1 . Certain mutations are preferentially selected (serine at position 5 and leucine at position 7), and no mutations have been detected at position 9, a second anchor residue (9, 42) . In our previous report, we showed that several of these changes abrogated recognition by lymphocytes derived from the brain and spinal cord in direct ex vivo cytotoxicity assays (28) , but it remains to be determined whether the apparent selection for certain mutations occurs because these changes result in CTL escape most effectively or if other factors, such as selection at the RNA level, also are important. The latter is improbable since the vast majority of the mutations which are detected encode amino acid changes and therefore are likely to be selected at the protein level.
